Influence of plasma exchange on rituximab pharmacokinetics.
作者信息
Azzopardi Nicolas, François Maud, Laurent Emeline, Paintaud Gilles, Birmelé Béatrice
机构信息
CNRS, UMR 7292, France; Université François-Rabelais de Tours, PRES Centre-Val de Loire Université, GICC, Tours, France.
出版信息
Br J Clin Pharmacol. 2013 Sep;76(3):486-8. doi: 10.1111/bcp.12167.
Abstract
摘要
相似文献
1
Influence of plasma exchange on rituximab pharmacokinetics.血浆置换对利妥昔单抗药代动力学的影响。
Br J Clin Pharmacol. 2013 Sep;76(3):486-8. doi: 10.1111/bcp.12167.
2
Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites.利妥昔单抗在大量腹水的滤泡性淋巴瘤治疗中在腹水和血清中的药代动力学。
Ann Hematol. 2012 Sep;91(9):1499-500. doi: 10.1007/s00277-012-1410-9. Epub 2012 Jan 28.
3
The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.¹³¹I-利妥昔单抗在一名CD20阳性非霍奇金淋巴瘤患者体内的药代动力学：放射性碘化对利妥昔单抗生物学特性影响的评估
Hum Antibodies. 2011;20(1-2):37-40. doi: 10.3233/hab20110240.
4
An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon.一名丙型肝炎病毒相关混合性冷球蛋白血症和惰性非霍奇金淋巴瘤患者，此前接受过干扰素治疗，在使用利妥昔单抗后，加用聚乙二醇干扰素和利巴韦林进行另一线治疗。
Blood Transfus. 2012 Jan;10(1):101-3. doi: 10.2450/2011.0006-11. Epub 2011 Jul 18.
5
[Subcutaneous Rituximab is effective and safe].皮下注射利妥昔单抗有效且安全。
Med Monatsschr Pharm. 2014 Jan;37(1):39-40.
6
Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.对于非霍奇金淋巴瘤患者，每2个月进行一次利妥昔单抗维持治疗比每3个月一次的毒性更大。
Blood. 2015 May 21;125(21):3354-5. doi: 10.1182/blood-2015-02-628362.
7
Rituximab in lymphoma with life threatening haemolysis.
Leuk Lymphoma. 2002 Aug;43(8):1711-2. doi: 10.1080/1042819021000003108.
8
HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Int J Hematol. 2012 May;95(5):588-91. doi: 10.1007/s12185-012-1050-9. Epub 2012 Mar 16.
9
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Clin Adv Hematol Oncol. 2012 Aug;10(8):540-2.
10
Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.美国非霍奇金淋巴瘤患者使用利妥昔单抗的更快输注：对护理实践的影响。
J Infus Nurs. 2013 May-Jun;36(3):172-8. doi: 10.1097/NAN.0b013e318288a103.
引用本文的文献
1
Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives.利妥昔单抗药代动力学和药效学改变在各种免疫介导性肾小球疾病中的意义及潜在的抗 CD20 治疗替代方案。
Front Immunol. 2022 Nov 7;13:1024068. doi: 10.3389/fimmu.2022.1024068. eCollection 2022.
2
Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange.治疗性血浆置换患者的药物剂量。
Neurocrit Care. 2021 Feb;34(1):301-311. doi: 10.1007/s12028-020-00989-1.
3
Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx.利妥昔单抗可使免疫性血小板减少性紫癜（iTTP）患者循环中的CD20+ T和B淋巴细胞早期清除，尽管TPO-RA仍在持续使用。
Blood Adv. 2020 Feb 11;4(3):477-481. doi: 10.1182/bloodadvances.2019001148.
4
Cancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations.癌症治疗学再探讨；靶向细胞信号通路的新型药物、全基因组关联研究及其他试验与磨难。
Br J Clin Pharmacol. 2013 Sep;76(3):317-9. doi: 10.1111/bcp.12216.
本文引用的文献
1
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.接受抢先使用利妥昔单抗治疗的异基因干细胞移植高危受者中，EB病毒血症的预后因素及结局
Transpl Infect Dis. 2013 Jun;15(3):259-67. doi: 10.1111/tid.12061. Epub 2013 Feb 13.
2
Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.利妥昔单抗治疗急性特发性血栓性血小板减少性紫癜的药代动力学。
J Thromb Haemost. 2010 Jun;8(6):1201-8. doi: 10.1111/j.1538-7836.2010.03818.x. Epub 2010 Feb 19.
3
Evaluation of a peptide ELISA for the detection of rituximab in serum.用于检测血清中利妥昔单抗的肽酶联免疫吸附测定法的评估
J Immunol Methods. 2007 Aug 31;325(1-2):127-39. doi: 10.1016/j.jim.2007.06.011. Epub 2007 Jul 17.
4
Rituximab therapy for acute humoral rejection after kidney transplantation.利妥昔单抗治疗肾移植术后急性体液性排斥反应
Transplantation. 2007 May 15;83(9):1277-80. doi: 10.1097/01.tp.0000261113.30757.d1.
5
Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient.肾移植受者多次血浆置换期间巴利昔单抗的序贯血药浓度监测
Transplant Proc. 2005 Mar;37(2):875-8. doi: 10.1016/j.transproceed.2005.01.050.
6
B cell depletion in autoimmune disease.自身免疫性疾病中的B细胞耗竭。
Arthritis Res Ther. 2003;5 Suppl 4(Suppl 4):S17-21. doi: 10.1186/ar1007. Epub 2003 Oct 2.
Zotero 插件